Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun 4;190(22):E677-E687.
doi: 10.1503/cmaj.170453.

The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver

Hemant Shah  1 , Marc Bilodeau  2 , Kelly W Burak  2 , Curtis Cooper  2 , Marina Klein  2 , Alnoor Ramji  2 , Dan Smyth  2 , Jordan J Feld  2 ; Canadian Association for the Study of the Liver
Affiliations

The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver

Hemant Shah et al. CMAJ. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: Hemant Shah reports personal fees from AbbVie, Gilead, Bristol-Myers Squibb, Intercept, Janssen, Merck, Roche and Lupin, and grants from Janssen and Boehringer Ingelheim, outside the submitted work. Marc Bilodeau reports personal fees from AbbVie, Gilead, GSK, Merck, Vertex and Roche, and grants from Merck and GSK, during the conduct of the study, and reports grants from Synageva, Verlyx and Bristol-Myers Squibb, and personal fees from Verlyx, outside the submitted work. Kelly Burak reports grants from Bayer, Verlyx and Lupin, and personal fees from Merck, Astellas, Bayer, Gilead and Amgen, outside the submitted work. Curtis Cooper reports grants and personal fees from Gilead, Merck and AbbVie, outside the submitted work. Marina Klein reports grants from ViiV Healthcare, Merck and Janssen, and consulting fees from ViiV Healthcare, Bristol-Myers Squibb, AbbVie and Merck. Alnoor Ramji reports a grant from Gilead; personal fees for clinical trials from AbbVie, Gilead, Janssen, Intercept, Lupin and Merck; and other fees from AbbVie, Bristol-Myers Squibb, Allergen, Gilead, Janssen, Intercept, Novartis and Merck, outside the submitted work. Dan Smyth reports personal fees from AbbVie, Merck and Gilead, and grants from AbbVie and Gilead, outside the submitted work. Jordan Feld reports grants and personal fees from AbbVie, Merck, Gilead and Janssen; personal fees from Contravir; and grants from Abbott, outside the submitted work. No other competing interests were declared.

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Myers RP, Liu M, Shaheen AA. The burden of hepatitis C virus infection is growing: a Canadian population-based study of hospitalizations from 1994 to 2004. Can J Gastroenterol 2008;22:381–7. - PMC - PubMed
    1. Myers RP, Krajden M, Bilodeau M, et al. Burden of disease and cost of chronic hepatitis C infection in Canada. Can J Gastroenterol Hepatol 2014;28:243–50. - PMC - PubMed
    1. Schanzer DL, Paquette D, Lix LM. Historical trends and projected hospital admissions for chronic hepatitis C infection in Canada: a birth cohort analysis. CMAJ Open 2014;2:E139–44. - PMC - PubMed
    1. Rotermann M, Langlois K, Andonov A, et al. Seroprevalence of hepatitis B and C virus infections: results from the 2007 to 2009 and 2009 to 2011 Canadian Health Measures Survey. Health Rep 2013;24:3–13. - PubMed
    1. Yoshida EM, Sulkowski MS, Gane EJ, et al. Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology 2015;61:41–5. - PubMed

MeSH terms